Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies
Highlights • Complement is activated in vivo when CD20 mAbs RTX or OFA are infused in CLL patients. • The detailed cellular events that occur in vitro during mAb-mediated CDC have been elucidated for CD20 mAbs. • New and innovative approaches should allow for development of far more effective comple...
Gespeichert in:
| Veröffentlicht in: | Seminars in immunology 2016-06, Vol.28 (3), p.309-316 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 316 |
|---|---|
| container_issue | 3 |
| container_start_page | 309 |
| container_title | Seminars in immunology |
| container_volume | 28 |
| creator | Taylor, Ronald P Lindorfer, Margaret A |
| description | Highlights • Complement is activated in vivo when CD20 mAbs RTX or OFA are infused in CLL patients. • The detailed cellular events that occur in vitro during mAb-mediated CDC have been elucidated for CD20 mAbs. • New and innovative approaches should allow for development of far more effective complement-fixing mAbs for cancer immunotherapy. |
| doi_str_mv | 10.1016/j.smim.2016.03.003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1811843499</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1044532316000105</els_id><sourcerecordid>1811843499</sourcerecordid><originalsourceid>FETCH-LOGICAL-c460t-8e18672d07807fe72e920412f71378857780b8a156e0237a08dae57edf4885743</originalsourceid><addsrcrecordid>eNp9kc2O1DAQhC0EYpeFF-CAcuSS0P5J7CCEhEbAIq3EAThbHqfDeojtwXYQ8_Y4zMKBAye32lUl9VeEPKXQUaDDi0OXvfMdq3MHvAPg98glhXFo-UDV_W0Wou054xfkUc4HqAqh6ENywSTAKBRckrA7lVjiT2cbj_bWBJd9buLcOO_XEMstJnM8vWyuTQqYswtfGxv9cUGPoTQuNFXRGFtcDJvLhOLasvqYGh9DtEsMZvm93cfJYX5MHsxmyfjk7r0iX969_by7bm8-vv-we3PTWjFAaRVSNUg2gVQgZ5QMRwaCsllSLpXqZd3vlaH9gMC4NKAmg73EaRbbr-BX5Pk595ji9xVz0d5li8tiAsY1a6ooVYKLcaxSdpbaFHNOOOtjct6kk6agN876oDfOeuOsgetKsZqe3eWve4_TX8sfsFXw6izAeuUPh0ln6zBYnFxCW_QU3f_zX_9jt4sLzprlG54wH-KaKth6h85Mg_60Nb0VTYdaMoWe_wL3jKQ3</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1811843499</pqid></control><display><type>article</type><title>Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Taylor, Ronald P ; Lindorfer, Margaret A</creator><creatorcontrib>Taylor, Ronald P ; Lindorfer, Margaret A</creatorcontrib><description>Highlights • Complement is activated in vivo when CD20 mAbs RTX or OFA are infused in CLL patients. • The detailed cellular events that occur in vitro during mAb-mediated CDC have been elucidated for CD20 mAbs. • New and innovative approaches should allow for development of far more effective complement-fixing mAbs for cancer immunotherapy.</description><identifier>ISSN: 1044-5323</identifier><identifier>EISSN: 1096-3618</identifier><identifier>DOI: 10.1016/j.smim.2016.03.003</identifier><identifier>PMID: 27009480</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Allergy and Immunology ; Animals ; Antibodies, Monoclonal - therapeutic use ; Antibody-Dependent Cell Cytotoxicity ; Antigens, Neoplasm - immunology ; Complement ; Complement Activation ; Complement System Proteins - metabolism ; Cytotoxicity, Immunologic ; Genetic Engineering ; Humans ; Immunotherapy - methods ; Immunotherapy of Cancer ; Monoclonal antibodies ; Neoplasms - immunology ; Neoplasms - therapy</subject><ispartof>Seminars in immunology, 2016-06, Vol.28 (3), p.309-316</ispartof><rights>Elsevier Ltd</rights><rights>2016 Elsevier Ltd</rights><rights>Copyright © 2016 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c460t-8e18672d07807fe72e920412f71378857780b8a156e0237a08dae57edf4885743</citedby><cites>FETCH-LOGICAL-c460t-8e18672d07807fe72e920412f71378857780b8a156e0237a08dae57edf4885743</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1044532316000105$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27009480$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Taylor, Ronald P</creatorcontrib><creatorcontrib>Lindorfer, Margaret A</creatorcontrib><title>Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies</title><title>Seminars in immunology</title><addtitle>Semin Immunol</addtitle><description>Highlights • Complement is activated in vivo when CD20 mAbs RTX or OFA are infused in CLL patients. • The detailed cellular events that occur in vitro during mAb-mediated CDC have been elucidated for CD20 mAbs. • New and innovative approaches should allow for development of far more effective complement-fixing mAbs for cancer immunotherapy.</description><subject>Allergy and Immunology</subject><subject>Animals</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibody-Dependent Cell Cytotoxicity</subject><subject>Antigens, Neoplasm - immunology</subject><subject>Complement</subject><subject>Complement Activation</subject><subject>Complement System Proteins - metabolism</subject><subject>Cytotoxicity, Immunologic</subject><subject>Genetic Engineering</subject><subject>Humans</subject><subject>Immunotherapy - methods</subject><subject>Immunotherapy of Cancer</subject><subject>Monoclonal antibodies</subject><subject>Neoplasms - immunology</subject><subject>Neoplasms - therapy</subject><issn>1044-5323</issn><issn>1096-3618</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc2O1DAQhC0EYpeFF-CAcuSS0P5J7CCEhEbAIq3EAThbHqfDeojtwXYQ8_Y4zMKBAye32lUl9VeEPKXQUaDDi0OXvfMdq3MHvAPg98glhXFo-UDV_W0Wou054xfkUc4HqAqh6ENywSTAKBRckrA7lVjiT2cbj_bWBJd9buLcOO_XEMstJnM8vWyuTQqYswtfGxv9cUGPoTQuNFXRGFtcDJvLhOLasvqYGh9DtEsMZvm93cfJYX5MHsxmyfjk7r0iX969_by7bm8-vv-we3PTWjFAaRVSNUg2gVQgZ5QMRwaCsllSLpXqZd3vlaH9gMC4NKAmg73EaRbbr-BX5Pk595ji9xVz0d5li8tiAsY1a6ooVYKLcaxSdpbaFHNOOOtjct6kk6agN876oDfOeuOsgetKsZqe3eWve4_TX8sfsFXw6izAeuUPh0ln6zBYnFxCW_QU3f_zX_9jt4sLzprlG54wH-KaKth6h85Mg_60Nb0VTYdaMoWe_wL3jKQ3</recordid><startdate>20160601</startdate><enddate>20160601</enddate><creator>Taylor, Ronald P</creator><creator>Lindorfer, Margaret A</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160601</creationdate><title>Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies</title><author>Taylor, Ronald P ; Lindorfer, Margaret A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c460t-8e18672d07807fe72e920412f71378857780b8a156e0237a08dae57edf4885743</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Allergy and Immunology</topic><topic>Animals</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibody-Dependent Cell Cytotoxicity</topic><topic>Antigens, Neoplasm - immunology</topic><topic>Complement</topic><topic>Complement Activation</topic><topic>Complement System Proteins - metabolism</topic><topic>Cytotoxicity, Immunologic</topic><topic>Genetic Engineering</topic><topic>Humans</topic><topic>Immunotherapy - methods</topic><topic>Immunotherapy of Cancer</topic><topic>Monoclonal antibodies</topic><topic>Neoplasms - immunology</topic><topic>Neoplasms - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Taylor, Ronald P</creatorcontrib><creatorcontrib>Lindorfer, Margaret A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Seminars in immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Taylor, Ronald P</au><au>Lindorfer, Margaret A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies</atitle><jtitle>Seminars in immunology</jtitle><addtitle>Semin Immunol</addtitle><date>2016-06-01</date><risdate>2016</risdate><volume>28</volume><issue>3</issue><spage>309</spage><epage>316</epage><pages>309-316</pages><issn>1044-5323</issn><eissn>1096-3618</eissn><abstract>Highlights • Complement is activated in vivo when CD20 mAbs RTX or OFA are infused in CLL patients. • The detailed cellular events that occur in vitro during mAb-mediated CDC have been elucidated for CD20 mAbs. • New and innovative approaches should allow for development of far more effective complement-fixing mAbs for cancer immunotherapy.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>27009480</pmid><doi>10.1016/j.smim.2016.03.003</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1044-5323 |
| ispartof | Seminars in immunology, 2016-06, Vol.28 (3), p.309-316 |
| issn | 1044-5323 1096-3618 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1811843499 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Allergy and Immunology Animals Antibodies, Monoclonal - therapeutic use Antibody-Dependent Cell Cytotoxicity Antigens, Neoplasm - immunology Complement Complement Activation Complement System Proteins - metabolism Cytotoxicity, Immunologic Genetic Engineering Humans Immunotherapy - methods Immunotherapy of Cancer Monoclonal antibodies Neoplasms - immunology Neoplasms - therapy |
| title | Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T22%3A44%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cytotoxic%20mechanisms%20of%20immunotherapy:%20Harnessing%20complement%20in%20the%20action%20of%20anti-tumor%20monoclonal%20antibodies&rft.jtitle=Seminars%20in%20immunology&rft.au=Taylor,%20Ronald%20P&rft.date=2016-06-01&rft.volume=28&rft.issue=3&rft.spage=309&rft.epage=316&rft.pages=309-316&rft.issn=1044-5323&rft.eissn=1096-3618&rft_id=info:doi/10.1016/j.smim.2016.03.003&rft_dat=%3Cproquest_cross%3E1811843499%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1811843499&rft_id=info:pmid/27009480&rft_els_id=S1044532316000105&rfr_iscdi=true |